Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic ... “Interchangeability of Selarsdi with Stelara will further enable increased access for ...

Formycon and its commercialization partner Fresenius Kabi have announced that the US Food and Drug Administration (FDA) has ...

“Interchangeability of Selarsdi with Stelara will further enable increased access for US patients to more affordable treatment options and contribute to lowering health care costs, which is an ...

PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE ...

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

Biocon had entered into a settlement and licensing agreement with Janssen Biotech Inc, Janssen Sciences Ireland and Johnson & ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara ... for the treatment of moderate to severe plaque psoriasis and active psoriatic ...

“Interchangeability of SELARSDI with Stelara will further ... moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. . the treatment of adults and pediatric ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced that the U.S. Food and Drug Administration (FDA ...